Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Vectus Biosystems is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vectus Biosystems has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Vectus Biosystems. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Vectus Biosystems's earnings available for a low price, and how does
this compare to other companies in the same industry?
Vectus Biosystems has negative assets, we can't compare the value of its assets to the AU Biotechs industry average.
Take a look at our analysis of VBS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Vectus Biosystems's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vectus Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Vectus Biosystems's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Vectus Biosystems's earnings growth to the Australia market average as no estimate data is available.
Unable to compare Vectus Biosystems's revenue growth to the Australia market average as no estimate data is available.
Unable to determine if Vectus Biosystems is high growth as no earnings estimate data is available.
Unable to determine if Vectus Biosystems is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Vectus Biosystems's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Vectus Biosystems's finances.
The net worth of a company is the difference between its assets and liabilities.
Vectus Biosystems's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Vectus Biosystems's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Vectus Biosystems's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Vectus Biosystems has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Karen Annette Duggan serves as the Chief Executive Officer of Vectus Biosystems Limited and has been its Executive Director since September 4, 2006. Dr. Duggan is the Founder of Vectus. She was formally Director of the Hypertension Service - South Western Sydney Area Health Service (SWSAHS), and was Chair of the National Blood Pressure and Vascular Disease Advisory Committee. She remains a member of the Cardiovascular Clinical Expert Reference Group of the NSW Department of Health. In her role as Director of the Hypertension Service SWSAHS, she was responsible for managing a multidisciplinary team (medical, nursing, laboratory and administrative staff), as well as developing and implementing new and innovative strategies in patient care within SWSAHS. Whilst Chair of the NBP&VDAC of the NHFA and a Member of The Executive of the HBPRCA, she set up the Australian Ambulatory Blood Pressure Collaboration, designed a national study and helped co-ordinate data collection and analysis. She has been a Director of Vectus since 2005. Her research has defined the mechanisms by which the body maintains sodium balance in the face of changing oral sodium intake as well as how these mechanisms are deranged in salt-sensitive hypertension. Her research has also defined a major mediator in the development of myocardial and renal fibrosis. She was also a member of the Cardiovascular Health Advisory Committee of the National Heart Foundation of Australia and the Post-Acute Stroke Guidelines Advisory Committee of the Australian Government Department of Health and Aging.
Karen's compensation has been consistent with company performance over the past year, both up more than 20%.
Karen's remuneration is lower than average for companies of similar size in Australia.
CEO & Executive Director
Board of Directors Tenure
Average tenure of the
board of directors in years:
The tenure for the Vectus Biosystems board of directors is about average.
Board of Directors
CEO & Executive Director
Non-Executive Deputy Chairman
Non Executive Director
Independent Non-Executive Director
Independent Non Executive Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Could The Vectus Biosystems Limited (ASX:VBS) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Vectus Biosystems Limited (ASX:VBS) have power over the company. … Check out our latest analysis for Vectus Biosystems ASX:VBS Ownership Summary, August 29th 2019 What Does The Institutional Ownership Tell Us About Vectus Biosystems? … Private Company Ownership Our data indicates that Private Companies hold 22%, of the company's shares.
What Kind Of Shareholders Own Vectus Biosystems Limited (ASX:VBS)?
Vectus Biosystems is a smaller company with a market capitalization of AU$8.2m, so it may still be flying under the radar of many institutional investors. … Insider Ownership Of Vectus Biosystems The definition of company insiders can be subjective, and does vary between jurisdictions. … Private Company Ownership Our data indicates that Private Companies hold 22%, of the company's shares.
Easy Come, Easy Go: How Vectus Biosystems (ASX:VBS) Shareholders Got Unlucky And Saw 72% Of Their Cash Evaporate
Vectus Biosystems Limited (ASX:VBS) shareholders should be happy to see the share price up 13% in the last month. … Vectus Biosystems didn't have any revenue in the last year, so it's fair to say it doesn't yet have a proven product (or at least not one people are paying for). … But with the share price diving 34% per year, over 3 years, it's probably fair to say that some shareholders no longer believe the company will succeed.
Do Directors Own Vectus Biosystems Limited (ASX:VBS) Shares?
The big shareholder groups in Vectus Biosystems Limited (ASX:VBS) have power over the company. … Generally speaking, as a company grows, institutions will increase their ownership. … Vectus Biosystems is not a large company by global standards.
Why Vectus Biosystems Limited's (ASX:VBS) Ownership Structure Is Important
In this article, I will take a quick look at Vectus Biosystems Limited’s (ASX:VBS) recent ownership structure – an unconventional investing subject, but an important one. … The impact of a company's ownership structure affects both its short- and long-term performance. … Therefore, it is beneficial for us to examine VBS's ownership structure in more detail.
Should You Worry About Vectus Biosystems Limited's (ASX:VBS) CEO Salary Level?
Therefore I will use earnings as a proxy of Duggan's performance in the past year. … In the past year, VBS produced negative earnings of -AU$3.12M. … Usually I'd use market cap and profit as factors determining performance, however, VBS's negative earnings lower the usefulness of my formula.
Who Are The Major Shareholders Of Vectus Biosystems Limited (ASX:VBS)?
Today, I will be analyzing Vectus Biosystems Limited’s (ASX:VBS) recent ownership structure, an important but not-so-popular subject among individual investors. … Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … Private Company Ownership Another important group of owners for potential investors in VBS are private companies that hold a stake of 21.42% in VBS.
Does Vectus Biosystems Limited's (ASX:VBS) Latest Financial Perfomance Look Strong?
See our latest analysis for Vectus Biosystems Did VBS's recent earnings growth beat the long-term trend and the industry? … For Vectus Biosystems, its latest trailing-twelve-month earnings is -AU$3.12M, which, relative to last year’s figure, has become less negative. … This means that, Vectus Biosystems has historically performed better than recently, despite the fact that it seems like earnings are now heading back in the right direction again.
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. Vectus Biosystems Limited was founded in 2005 and is based in Rosebery, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.